Cyteir Therapeutics

Investment area
Novo Ventures
Region
Eastern USA
Date of investment
August 2019

Cyteir Therapeutics is developing the next generation of synthetic lethal therapies targeting cancers and autoimmune diseases with specific gain-of-function abnormalities. Our current lead program targets RAD51 to induce synthetic lethality in diseases with a gain-of-function in the gene AID (also called AIDCA).

Cyteir Therapeutics

Investment area
Novo Ventures
Region
Eastern USA
Date of investment
August 2019

Cyteir Therapeutics is developing the next generation of synthetic lethal therapies targeting cancers and autoimmune diseases with specific gain-of-function abnormalities. Our current lead program targets RAD51 to induce synthetic lethality in diseases with a gain-of-function in the gene AID (also called AIDCA).

Cyteir Therapeutics

Investment area
Novo Ventures
Region
Eastern USA
Date of investment
August 2019

Cyteir Therapeutics is developing the next generation of synthetic lethal therapies targeting cancers and autoimmune diseases with specific gain-of-function abnormalities. Our current lead program targets RAD51 to induce synthetic lethality in diseases with a gain-of-function in the gene AID (also called AIDCA).